Centre d'Esclerosi Múltiple de Catalunya, CEM-Cat, Unitat de Neuroimmunologia Clínica, Hospital Universitari Vall d'Hebron, Barcelona, Spain.
Curr Neurol Neurosci Rep. 2011 Oct;11(5):484-91. doi: 10.1007/s11910-011-0211-1.
Notwithstanding the availability of disease-modifying treatments including interferon-β, glatiramer acetate, and natalizumab, a considerable proportion of multiple sclerosis (MS) patients experience continued progression of disease, clinical relapses, disease activity on MRI, and adverse effects. Application of gene expression, proteomic or genomic approaches is universally accepted as a suitable strategy toward the identification of biomarkers with predictive value for beneficial/poor clinical response to therapy and treatment risks. This review focuses on recent progress in research on the pharmacogenomics of disease-modifying therapies for MS. Although MS drug response biomarkers are not yet routinely implemented in the clinic, the diversity of reported, promising molecular markers is rapidly increasing. Even though most of these markers await further validation, given time, this research is likely to empower neurologists with an enhanced armamentarium to facilitate rational decisions on therapy and patient management.
尽管有多种疾病修饰治疗方法，包括干扰素-β、那他珠单抗和醋酸格拉替雷，相当一部分多发性硬化症 (MS) 患者仍会出现疾病持续进展、临床复发、MRI 上的疾病活动和不良反应。基因表达、蛋白质组学或基因组学方法的应用被普遍认为是识别具有治疗获益/不良临床反应和治疗风险预测价值的生物标志物的合适策略。本综述重点介绍多发性硬化症疾病修饰治疗的药物基因组学研究的最新进展。尽管 MS 药物反应生物标志物尚未在临床上常规应用，但报告的有前途的分子标志物的多样性正在迅速增加。尽管这些标志物中的大多数仍有待进一步验证，但随着时间的推移，这项研究很可能使神经科医生拥有更强大的工具，从而能够做出更合理的治疗决策和患者管理。
